Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha - Swedish Orphan Biovitrim

Drug Profile

Interferon alpha - Swedish Orphan Biovitrim

Alternative Names: HuIFN-alpha-Le; Leu-IFN; Multiferon

Latest Information Update: 24 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Viragen
  • Developer Swedish Orphan Biovitrum; Viragen
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Hairy cell leukaemia; Hepatitis B; Hepatitis C; Malignant melanoma
  • Discontinued Influenza virus infections

Most Recent Events

  • 24 Mar 2015 The product is approved for Malignant melanoma in Europe
  • 30 Oct 2014 Swedish Orphan Biovitrum announces its decision to cease manufacturing of Multiferon® and close its production site in Umeå
  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top